Skip to main content
Hendrik Scholl, MD, Ophthalmology, Baltimore, MD, Johns Hopkins Howard County Medical Center

HendrikPeterSchollMD

Ophthalmology Baltimore, MD

Retinal Disease

Professor of Ophthalmology, Johns Hopkins University School of Medicine; Director, Retinal Degeneration Clinic, Dr. Frieda Derdeyn Bambas Professor of Ophthalmology, Director, Visual Neurophysiology Service, Co-director, Johns Hopkins Center for Stem Cells and Ophthalmic Regenerative Medicine (STORM)

Dr. Scholl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Scholl's full profile

Already have an account?

Education & Training

  • Brown University
    Brown UniversityResidency, Ophthalmology, 1996 - 1997
  • Brown University
    Brown UniversityElectrophysiology, 1996 - 1997
  • Eberhard-Karls Univiversity
    Eberhard-Karls UniviversityMD, MA, 1989 - 1997
  • Eberhard-Karls Univiversity
    Eberhard-Karls UniviversityMD, MA, Medicine, Philosophy, 1989 - 1997
  • Eberhard-Karls Univiversity
    Eberhard-Karls UniviversityMD, MA, Medicine, Philosophy, Magna Cum Laude, 1989 - 1997
  • Eberhard-Karls University
    Eberhard-Karls UniversityMD, MA, Medicine, Philosophy, Magna Cum Laude, 1989 - 1997
  • Eberhard Karls University Faculty of Medicine
    Eberhard Karls University Faculty of MedicineClass of 1997, MD, MA

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2010 - 2017

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Earlier Role for Complement C3 Inhibitor in AMD?
    Earlier Role for Complement C3 Inhibitor in AMD?February 8th, 2022
  • Reversing Blindness: Award for Cone Optogenetics Gene Therapy
    Reversing Blindness: Award for Cone Optogenetics Gene TherapyApril 29th, 2021
  • Acucela Initiates Phase 2a Study of Emixustat Hydrochloride Addressing Patients with Stargardt Disease
    Acucela Initiates Phase 2a Study of Emixustat Hydrochloride Addressing Patients with Stargardt DiseaseJanuary 26th, 2017

Professional Memberships

Other Languages

  • German

Hospital Affiliations